中文
| Catalogue |
|
|
| Recommend Products |
Company News
- Junshi Biosciences Announces Toripalimab’s Approval in Singapore 3/27/2025
- Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizu... 3/24/2025
- Junshi Biosciences Announces Toripalimab’s Approval in Australia 1/20/2025
- Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab 11/16/2024
- Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and Chin... 10/16/2024
- Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab 9/25/2024
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP Fo... 7/30/2024
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatme... 6/26/2024
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatme... 6/18/2024
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab 4/25/2024
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatme... 4/8/2024
- Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences A... 2/2/2024
- Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Torip... 7/12/2023
- Junshi Biosciences Announces Approval for Marketing of VV116 in China 1/31/2023
- Junshi Biosciences Announces Acceptance of NDA for VV116 in China 1/18/2023
- Junshi Biosciences Announces Submission of a Marketing Authorization Application for Torip... 11/25/2022
- Junshi Biosciences Announces Submission of a Marketing Authorization Application to the Eu... 11/15/2022
- Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab 5/17/2022
- Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Repl... 7/20/2021
- Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer 7/2/2021